𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term Safety, Tolerability and Efficacy of Daclizumab (Zenapax®) in a Two-dose Regimen in Liver Transplant Recipients

✍ Scribed by Gerit Niemeyer; Martina Koch; Susan Light; Ernst R. Kuse; Bjoern Nashan

Book ID
119979629
Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
116 KB
Volume
2
Category
Article
ISSN
1600-6135

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of renal function in liver tr
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial
✍ Eric M. Yoshida; Paul J. Marotta; Paul D. Greig; Norman M. Kneteman; Denis Marle 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Posttransplant chronic renal failure, secondary to calcineurin inhibitor agents, is emerging as a major problem in liver transplantation. We report a randomized clinical trial comparing daclizumab, delayed low-dose tacrolimus (target trough level 4-8 ng/mL, starting day 4-6), Investigational Arm (n

A novel three-dose regimen of daclizumab
A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study
✍ W. Kenneth Washburn; Lewis W. Teperman; Thomas G. Heffron; David D. Douglas; Ste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB

This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3-dose regimen of daclizumab in de novo hepatitis C liver transplant recipients. In 30 of 156 recipients receiving daclizumab, mycophenolate mofetil, tacrolimus, and no steroids (Arm 3 of Hep C 3 Liver Study), daclizumab (2, 2

Safety, tolerability, and efficacy of ev
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results
✍ Gary Levy; Heinz Schmidli; Jeffrey Punch; Elizabeth Tuttle-Newhall; David Mayer; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 grou